Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Acetaminophen in the Intensive Care Unit.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Generally to be considered for this study one must be critically ill, febrile, and can safely either receive acetaminophen or have acetaminophen withheld. Also one must not have conditions that would alter normal drug absorption or normal thermoregulation. Specifically the eligibility criteria are:~INCLUSION CRITERIA:~* Adult patients (\> 18 years) admitted to Intensive Care Unit at Vancouver Hospital with a core temperature \> 38.3 °C for 2 or more consecutive hours, but not longer than 48 hours\*~* Continuous arterial pressure monitor in place at the time of intervention and data collection~* Patients may only participate in the study once~* To remain in the ICU for the entire study period (2 hours prior to drug administration to 4 hours post drug administration)~EXCLUSION CRITERIA:~* Significant liver dysfunction~* Acute neurological injury~* Seizure disorder~* Cardiomyopathy, elevated cardiac enzymes indicative of an acute cardiac injury, electrocardiogram (ECG) changes indicative of cardiac ischemia (i.e., ST segment elevation/depression)~* Hemodynamic instability (requiring fluid boluses, or change/initiation of vasopressors. Patients receiving steady doses of vasopressor support may be included)~* Severe hypoxemia, (fraction of inspired oxygen (FiO2) requirements of more than 60% to maintain hemoglobin oxygen saturation (SaO2) \> 90% or partial pressure of oxygen in the blood (PaO2) \> 70)~* Temperature \> 40.0 °C~* Receiving external cooling~* Haemodialysis, plasma exchange, or any treatment where the blood is taken out of the body and processed~* Acute thermal injury to skin (i.e., burn)~* Gut malabsorption (i.e., receiving \< 40% required calories enterally)~* Receiving medications that have known antipyretic effects (acetaminophen, ibuprofen, steroids, etc.)~* Physician opposed to enrolment in the study~NOTE: in response to very low enrollment 2 exclusion criteria were changed on Nov 5, 2015. These were:~1. patients no longer needed to recieve 40% of required calories enterally, instead patients who were not receiving any caloric intake via the gut could be enrolled as long as they were still permitted to receive oral medications.~2. patients no longer had to have acetaminophen discontinued upon enrollment. They could not be receiving it regularly but could still receive acetaminophen on an as needed (PRN) basis as long as it could be safely withheld for up to 12 hours if they developed a fever.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): This group consists of stable but febrile ICU patients (temp \>38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
- Acetaminophen Group (Type: EXPERIMENTAL): This group consists of stable but febrile ICU patients (temp \>38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).